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Human noroviruses (NoVs) are the primary cause of acute gastroenteritis and are charac-
terized by antigenic variation between genogroups and genotypes and antigenic drift of
strains within the predominant GII.4 genotype. In the context of this diversity, an effective
NoV vaccine must elicit broadly protective immunity. We used an antibody (Ab) binding
blockade assay to measure the potential cross-strain protection provided by a multivalent
NoV virus-like particle (VLP) candidate vaccine in human volunteers.
Methods and Findings
Sera from ten human volunteers immunized with a multivalent NoV VLP vaccine (genotypes
GI.1/GII.4) were analyzed for IgG and Ab blockade of VLP interaction with carbohydrate li-
gand, a potential correlate of protective immunity to NoV infection and illness. Immunization
resulted in rapid rises in IgG and blockade Ab titers against both vaccine components and
additional VLPs representing diverse strains and genotypes not represented in the vaccine.
Importantly, vaccination induced blockade Ab to two novel GII.4 strains not in circulation at
the time of vaccination or sample collection. GII.4 cross-reactive blockade Ab titers were
more potent than responses against non-GII.4 VLPs, suggesting that previous exposure
history to this dominant circulating genotype may impact the vaccine Ab response. Further,
antigenic cartography indicated that vaccination preferentially activated preexisting Ab re-
sponses to epitopes associated with GII.4.1997. Study interpretations may be limited by the
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Conclusions
Vaccination with a multivalent NoV VLP vaccine induces a broadly blocking Ab response to
multiple epitopes within vaccine and non-vaccine NoV strains and to novel antigenic vari-
ants not yet circulating at the time of vaccination. These data reveal new information about
complex NoV immune responses to both natural exposure and to vaccination, and support





Diarrheal disease is a significant global health problem with an estimated 1.7 billion annual
cases. Symptoms from infection range from dehydration to malnutrition and even to early
death, particularly among children less than 5 y old and older adults [1]. Norovirus (NoV)
strains are responsible for about 50% of global outbreaks of gastroenteritis and cause an esti-
mated 21 million infections per year in the United States alone [2]. Although most NoV infec-
tions result in illness of modest severity, infection in children, older adults, immune-
compromised individuals, and individuals with underlying medical conditions such as malnu-
trition can have severe and even fatal consequences [3–13]. In addition to benefitting these par-
ticularly vulnerable populations, an effective NoV vaccine would also benefit members of the
military, travelers, and childcare, healthcare, and food industry workers.
NoVs are positive-sense, single-stranded RNA viruses in the Caliciviridae family, with gen-
ogroups GI and GII causing almost all human infections. Although new approaches to classifi-
cation have been suggested [14], NoV genotyping is based primarily on the amino acid
sequence of the major capsid protein (VP1) encoded by ORF 2 [15]. The genogroups are fur-
ther subdivided into a total of 30 different known genotypes. The GII.4 NoV strains cause
70%–80% of documented NoV outbreaks and account for the largest percentage of long-term-
care-facility- and vacation-related (e.g., cruise ship) outbreaks [2]. GII strains other than GII.4
cause more food-service- and community-related outbreaks than the less frequent GI strains
[2], though both GI and GII strains are routinely detected in outbreak investigations.
NoVs are non-enveloped, small, round, structured viruses. Expression of the ORF 2 se-
quence results in abundant capsid protein production. These proteins self-assemble into icosa-
hedral virus-like particles (VLPs) that are morphologically and antigenically indistinguishable
from native virions [16,17]. The NoV major capsid protein is divided into the shell and pro-
truding domains. The surface-exposed P2 subdomain (residues 279–405) [17] interacts with
histoblood group antigens (HBGAs) expressed on gut epithelial cells, facilitating virus binding
and entry resulting in infection [18]. Gut HBGA expression is largely dependent upon a func-
tional secretor enzyme (secretor-positive phenotype). Individuals lacking a functional secretor
enzyme are secretor-negative and at reduced risk of NoV infection. In the absence of a robust
cell culture or small animal model, NoV VLPs serve as surrogate viruses in immunological and
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biochemical assays, including an in vitro assay of antibody (Ab) blockade of VLP–HBGA inter-
action. The blockade assay is useful in identifying Abs that functionally block binding of NoV
capsid protein to carbohydrate ligands; these Abs are a subset of serum Abs that bind to the
VLPs as identified by enzyme immunoassay (EIA) [19,20]. The blockade assay has been inves-
tigated for clinical relevance and holds promise as a surrogate neutralization assay, as shown in
both infected chimpanzees [21] and Norwalk-virus-challenged human participants as a com-
ponent of protective immunity [22,23].
The ORF 2 gene of GII.4 strains is evolving via epochal evolution, a pattern of change char-
acterized by circulating strain replacement with a newly emergent strain, followed by a period
of relative stasis [19,24]. Resulting new predominant GII.4 NoV strains (see Fig. 1) can have al-
tered antigenicity and potentially altered ligand binding profiles [19]. Within the major capsid
protein gene of GII.4 strains, residues of the P2 subdomain are under selective pressure by the
host immune response; this pressure is one potential mechanism that drives viral evolution, re-
sulting in strain antigenic drift and escape from herd immunity [19,25–28]. We have identified
three GII.4-specific, evolving blockade Ab epitopes. Epitope A is hypervariable, and loss of epi-
tope A blockade Abs correlates with viral escape from herd immunity [20,25,27,29]. Epitope D
is less variable and, importantly, also modulates the ligand binding properties of GII.4 strains,
explaining altered HBGA binding patterns in evolving strains [19,25,30]. Epitope E is a con-
firmed Farmington Hills–specific blockade epitope [31]. Epitope F is conserved across all GII.4
strains measured to date. The amino acid coordinates of epitope F are not yet known, but we
have both human and mouse monoclonal antibodies (mAbs) that recognize this epitope and
have identified a domain (the NERK motif) within the capsid that regulates Ab access to epi-
tope F [25,32]. Additional factors, including inter-strain recombination [33] and polymerase fi-
delity [34,35], may also contribute to GII.4 predominance. Unfortunately, the lack of a well-
established virus propagation method excludes evaluation of the effect of these factors on viral
fitness. In contrast to the GII.4 strains, the other NoV genotypes do not appear to be evolving
via epochal evolution.
The most significant obstacles to development of an effective NoV vaccine are the large
number of antigenic variants, an incomplete understanding of the components of protective
immunity, and the unknown effect of a lifetime of NoV pre-exposure history on vaccine re-
sponse and, consequently, the unknown effect of vaccination on response to circulating NoVs.
Further, the effect of host genetic susceptibility to NoV infection on vaccine performance is
also undefined. A monovalent NoV GI.1 vaccine based on Norwalk virus VLPs was demon-
strated to be well tolerated and effective at limiting the risk of Norwalk virus illness and infec-
tion upon oral challenge [23,36]. Two doses of this VLP candidate vaccine reduced the rate of
symptomatic infection by 47% and the overall rate of infection by 26%. Serum blockade Ab ti-
ters above 200 were associated with a 72% reduction in frequency of illness and a 57% reduc-
tion in infection, providing evidence that pre-challenge blockade Ab titers correlated to
protection following vaccination and challenge in human volunteers [23]. Despite these posi-
tive results, a threshold for protection using serum blockade Ab titer has not been established,
and because the assay format is not yet standardized, it remains difficult to compare blockade
titers from study to study.
These initial findings in monovalent VLP vaccination studies were expanded upon in a fol-
low-up age and dose escalation study of a multivalent VLP candidate vaccine composed of
GI.1 and a GII.4 consensus VLP (GII.4C). GII.4C is an engineered VLP composed of the con-
sensus sequence of three NoV GII.4 strains that circulated in 2002 and 2006 (see Fig. 1). The
multivalent vaccine was observed to be well tolerated and to elicit Ab responses in adults. Four
dosages (5/5, 15/15, 50/50, and 150/150 μg GI.1/GII.4C VLP) of the multivalent vaccine were
compared in a group of individuals aged 18–49 y, and the three highest dosages elicited similar
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Ab responses and reactogenicity [37]. Although secretor-negative participants had lower base-
line titers against the vaccine antigens, they responded similarly to secretor-positive partici-
pants in titer and geometric mean fold rise (GMFR) [37], supporting in vitro [38] and in vivo
[39–41] evidence that some GI and GII NoV strains bind to secretor-negative carbohydrates
and infect the secretor-negative population. The 50/50-μg (GI.1/GII.4C) VLP dose was chosen
for further study in a human challenge model with a GII.4.2002 strain [42]. Peak Ab titers to
both vaccine components were observed after a single dose of vaccine, suggesting that vaccine-
induced Ab responses may not rise above a maximum level. Despite high Ab responses, vacci-
nated individuals were not significantly protected from illness or infection compared to the
placebo group. However, disease severity was significantly reduced. Interpretation of these re-
sults is complicated by a lower than expected infection rate and the absence of reporting of
blockade Ab titers.
In this study we evaluated the potential cross-strain immunity induced by the multivalent
candidate vaccine by measuring cross-reactive IgG and blockade Ab titers against the vaccine
components, two additional GI VLPs, 2 GII VLPs, and five GII.4 VLPs not included in the
vaccine formulation.
Fig 1. Temporal relationship between epidemiologically important GII.4 strains, relative to the virus-like particles and sera used in this study. The
vaccine GII.4 component (GII.4C) is a consensus VLP composed of GII.4.2002, GII.4.2006a, and GII.4.2006b sequences. GII.4.2006b.P.D302 represents a
strain that evolved in vivo and was isolated from an immune-compromised person.
doi:10.1371/journal.pmed.1001807.g001
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Materials and Methods
Ethics Statement
This follow-up study used de-identified human samples under University of North Carolina
institutional review board exemption approval #11-0883. Original samples were collected by
Takeda Vaccines under approval by institutional review boards at Saint Louis University
School of Medicine, Saint Louis, Missouri; University of Rochester School of Medicine and
Dentistry, Rochester, New York; and the Navy Medical Research Center, Silver Springs, Mary-
land, and participants provided written informed consent.
Serum Samples
Serum samples were collected from participants in a NoV vaccine dose–response study con-
ducted by Takeda Vaccines (Deerfield, Illinois) [37]. The results of that study guided selection
of the 50-μg/VLP dose as the formulation to test in a human challenge trial (Table 1 and [42]).
The 50-μg/VLP dose group of Cohort A (group A3) included ten adults aged 18–49 y vaccinat-
ed in January 2011 with an intramuscular injection of 50 μg of both GI.1 and GII.4C VLPs
adjuvanted with 3-O-deacylated monophosphoryl lipid A (GlaxoSmithKline) and aluminum
hydroxide (Brenntag Biosector, Denmark) on day 0 (dose 1), followed by an identical booster
vaccination on day 28 (dose 2). All serum samples collected from the ten participants on day 0,
7, 21, 35, and 180 after dose 1 were evaluated. S1 and S2 Figs. list the total number of samples
collected and evaluated for each VLP response by individual and assay. As a group, the Cohort
A individuals receiving placebo (PBS without adjuvant) were sero-positive at baseline but did
not mount serum responses to the vaccine antigens [37], therefore sera from this group were
not included in further analyses of cross-reactive Ab responses. Serum samples were provided
blinded of all participant identifiers. A set volume of each serum sample was provided for these
exploratory studies.
Virus-Like Particles
A diverse panel of VLPs was used in this study (Fig. 2). Except for GII.4C VLPs, ORF 2 genes
were inserted directly into the VEE replicon vector for the production of virus replicon parti-
cles, as previously described [27,31]. VLPs were expressed in BHK cells and purified by velocity
sedimentation in sucrose followed by simultaneous concentration and dialysis into PBS using
100-kDa MWCO centrifugal filter units (Millipore), if needed. GII.4C VLPs were provided by
Takeda Vaccines and produced in the baculovirus system. VLP protein concentrations were
determined by the BCA Protein Assay (Pierce). All of the VLPs used in this study bind to li-
gands found in porcine gastric mucin (PGM) type III, with the exception of GII.2. Although
bioinformatics analyses do not suggest why, GII.2 does not bind to any identified HBGA
sources except human type A and B saliva [43]; therefore, blockade assays were not performed
for this VLP.
Virus-Like-Particle-Specific Enzyme Immunoassay
EIA plates were coated with 0.25 μg/ml VLP in PBS before adding 2-fold serial dilutions of
serum. The primary Ab incubation was followed by anti-human-IgG-HRP secondary Ab (GE
Healthcare), and positive wells were color-developed with Ultra TMB substrate (Thermo Sci-
entific). Plates were washed with PBS/0.05% Tween 20 (Thermo Scientific) between steps, and
Ab dilutions were done in 5% Blotto/PBS/0.05% Tween 20. All incubations were done at room
temperature. The percent maximum binding was calculated, sigmoidal dose–response curves
fit to the data, and EC50 values determined using GraphPad Prism version 6.02 for Windows
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(GraphPad Software). All samples were tested in a minimum of two independent assays. EC50
titers below the lower limit of detection (100) were assigned a titer of 50.
Carbohydrate-Binding Blockade Assay
As described previously [20,25], EIA plates were coated with 10 μg/ml PGM type III (Sigma Al-
drich) diluted in PBS and blocked with 5% Blotto in PBS/0.05% Tween 20. VLPs (0.5 μg/ml)
were pretreated with decreasing concentrations of serum for 1 h before being added to the car-
bohydrate-ligand-coated plates for 1 h. Ligand-bound VLP was detected with rabbit anti-GI
or -GII or -GII.4 VLP hyperimmune serum followed by anti-rabbit-IgG-HRP (GE Healthcare).
All tested VLPs, except for GII.4.2012 and GII.4.2006b.P.D302, were components of the VLP
cocktails used to immunize rabbits. Multivalent GII.4 VLP immunization resulted in broadly
reactive serum that recognizes GII.4.2012 and GII.4.2006b.P.D302 [44]. Wash steps, Ab dilu-
tions, and color development were completed as described above. All incubations were done at
room temperature. The percent control binding was defined as the binding level in the pres-
ence of Ab pretreatment divided by the binding level in the absence of Ab pretreatment
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Group A3 was further evaluated in the current study.
aNumbers indicate data collected from blood draws: (1) serology for anti-NoV-specific GI.1 and GII.4 Ab titers, (2) Ab-secreting cells (ASCs) and homing
markers (fresh peripheral blood mononuclear cells [PBMCs]—single site only), (3) ASCs (cryopreserved PBMCs—all sites in Cohort A), (4) memory B
cells (cryopreserved PBMCs—all sites in Cohort A), and (5) cellular immune responses (cryopreserved PBMCs—all sites in Cohort A).
doi:10.1371/journal.pmed.1001807.t001
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multiplied by 100. Blockade data were fit using sigmoidal dose–response analysis of nonlinear
data in GraphPad Prism 6.02. EC50 values were calculated for sera that demonstrated blockade
of at least 50% at the dilution series (40–20480) tested. Sera that did not block 50% of binding
at the highest concentration tested were assigned an EC50 of 20 for statistical comparison.
Cartography
As described previously [45], we utilized multi-dimensional scaling (MDS) to analyze and visu-
alize the relationships between Ab titers against VLPs across the serum samples from this
study. This approach allows for data of large dimensions (e.g., multiple serological responses
across a range of individuals) to be “shrunk” down to a more manageable number of dimen-
sions for analysis, while maintaining accurate relationships between data points. Briefly, the
IgG EC50 titers of each serum against a panel of VLPs (Fig. 2) were normalized to the maxi-
mum response of each serum, as well as to the maximum overall titers across sera (normaliza-
tion method 1 [46]; the same normalization was used for the blockade Ab EC50 titers). We
calculated Euclidean distances, D, between each pair of Ab titers against VLPs. We utilized
MDS to then identify XYZ coordinates that maintain the underlying Euclidean distances. We
used Matlab 8.1’s (MathWorks) cmdscale function for the MDS. We used R (http://www.r-
project.org) and the rgl package for 3-D visualization of our data, as well as for statistical analy-
sis of the antigenic cartography data. Because of the unique nature of the D values (that they
belong to pairs of data points instead of to singular data points), in most cases we focus our sta-
tistical analyses on contrasting D values within specific groups of interest with D values be-
tween specific groups of interest (e.g., D values within either GI or GII VLPs versus D values
between GI and GII VLPs). Unless noted otherwise, these tests take the form of a set of t-tests
within a time point/assay combination, and we report as significant only those tests that pass
an ad hoc Bonferroni correction (p = 0.05/number of tests done within a time point/assay
combination).
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Blocking of Binding Assay
EIA plates were coated with 0.25 μg/ml GII.4.1997 or GII.4.2006b VLP, and serum samples
were added to VLP-coated plates at serial 2-fold dilutions. After 1 h, mouse mAbs to epitope A
(GII.4.1987.G1 [26] or GII.4.2006.G2 [26]) or epitope F (GII.4.2002.G5 [32]; MAB227P from
Maine Biotechnology Services) were added and incubated at room temperature for 1 h. Bound
mouse mAb was detected with sheep anti-mouse-IgG-HRP (GE Healthcare). Plates were
washed, the color developed, and the amount of serum (1/serum dilution) needed to block 50%
of the mAb binding (EC50) determined as described above for EIAs.
Statistical Analysis
Statistical analyses were done using GraphPad Prism 6.02 and SAS (version 9.3) unless other-
wise noted. For serum IgG and blockade Ab titers, geometric mean titer (GMT), GMFR from
baseline, and the seroresponse frequency were calculated for each group. The changes in
GMFR from baseline were tested using a paired t-test of the log values. Seroresponse was de-
fined as a4-fold increase above baseline titer. Generalized estimating equations (GEEs) were
used to estimate the relative risk of (1) a 4-fold increase in blockade Ab titers at day 7 compared
to day 0 given baseline titers above or below the assay limit of detection, for any VLP and (2)
day 7 titers above or below the assay limit of detection given baseline titers above or below the
assay limit of detection, for any VLP, along with corresponding chi-squared p-values. GEEs
were used to account for the correlated data points (specimens collected at different follow-up
time points from the same participant are correlated), as opposed to linear regression, which
assumes independent data points.
Results
Vaccination with the Multivalent Virus-Like Particle Candidate Vaccine
Results in Cross-Strain-Reactive IgG Responses
Based on results from a dose escalation study in adults aged 18–49 y (Table 1 and [37]), the 50-μg
GI.1/GII.4C VLP vaccine formulation was chosen for further study. Complete demographic in-
formation for the group in the dose escalation study that received this dose (Group A3) compared
to the other dose groups is provided in Table 2. As the vaccine target population will not be pre-
screened for secretor status and some NoV strains infect secretor-negative individuals [39–41],
secretor-negative participants were included in the larger dose escalation cohort and Group A3
(four out ten participants). Complete data comparing IgG and blockade Ab responses by secretor
status, day, and VLP are provided in S1 and S2 Figs. As reported for the full study [37], Ab re-
sponses between the secretor-negative and secretor-positive participants in Group A3 were gen-
erally not significantly different in GMT or GMFR, beyond the exceptions discussed below.
To measure the potential cross-strain protection provided by the multivalent NoV VLP vac-
cine, we retrospectively analyzed serum samples from the ten participants in the 50-μg dose
group from the dose escalation study for cross-reactive IgG and blockade Ab titer to VLPs rep-
resenting three different GI genotypes; five time-ordered, antigenically distinct GII.4 strains;
and two additional non-GII.4 GII genotypes (Fig. 2). Participants received a dose of adjuvanted
vaccine on day 0 and day 28. Sera collected on day 0 (before vaccine dose 1), day 7 after vaccine
dose 1, day 35 (7 d after vaccine dose 2), and day 180 (6 mo after vaccine dose 1) were evaluated
from each of the ten participants. One participant failed to return for the day 180
sample collection.
As a group (Fig. 3), the baseline IgG GMTs to GI types were relatively low, with significant
increases in GMFRs at day 7, 35, and 180 after dose 1. Titers peaked at day 7 post-vaccination,
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rising 10.3-fold for GI.1, 7.4-fold for GI.3, and 7.6-fold for GI.4. Despite a booster vaccination
at day 28, day 35 IgG titers were generally lower than day 7 titers, with GMFRs of 12-, 4-.
and 4.4-fold for GI.1, GI.3, and GI.4, respectively. At day 180, GMFRs were 4.1-fold for GI.1,
2.3-fold for GI.3, and 2.1-fold for GI.4. Secretor-negative participants had significantly less titer
to GI.4 at day 0 and to GI.1 at day 0 and day 180, possibly reflecting less infection history with
these strains (S1 Fig.). At day 7, the IgG seroresponse rate was 8/10 for GI.1 and GI.3 and 7/10
for GI.4 (Figs. 3 and S3). At day 35, 10/10 participants seroresponded for GI.1, and 5/10 for the
other GI VLPs, and these responses persisted at day 180 in 5/9 participants for GI.1, 2/9 for
GI.3, and 1/9 for GI.4.
The IgG response among different strains of GII.4 VLPs was relatively consistent (Fig. 3),
with no significant differences in GMFR between GII.4 VLPs at any time point. As a group,
GII.4 baseline GMTs were relatively low and in the same range as the GI titers, with significant
Table 2. Demographics of the Cohort A dose groups in the dose escalation study.
Characteristic Group A1: 5/5-μg
VLP Vaccine (n =
10)
Group A2: 15/15-μg
VLP Vaccine (n =
10)
Group A3: 50/50-μg
VLP Vaccine (n =
10)
Group A4: 150/150-







Male 3 (30) 4 (40) 3 (30) 2 (22) 1 (11) 13 (27)
Female 7 (70) 6 (60) 7 (70) 7 (78) 8 (89) 35 (73)
Ethnicity
Non-Hispanic 8 (80) 10 (100) 10 (100) 9 (100) 9 (100) 46 (96)




0 0 0 0 0 0
Asian 0 0 2 (20) 2 (22) 0 4 (8)
Hawaiian/Pacific
Islander
0 0 0 0 0 0
Black/African
American
2 (20) 2 (20) 2 (20) 1 (11) 2 (22) 9 (19)
White 8 (80) 7 (70) 6 (60) 6 (67) 7 (78) 34 (71)
Multi-racial 0 1 (10) 0 0 0 1 (2)




33 (9) 31 (11) 31 (8) 32 (9) 33 (13) 32 (10)
Median 32 30 37 34 27 32
Minimum, maximum (23, 46) (19, 46) (22, 42) (23, 49) (19, 49) (19, 49)
Saliva secretor
status
Positive 7 (70) 8 (80) 6 (60) 9 (100) 8 (89) 38 (79)
Negative 3 (30) 2 (20) 4 (40) 0 1 (11) 10 (21)
Blood type
A 3 (30) 3 (30) 5 (50) 3 (33) 2 (22) 16 (33)
B 0 1 (10) 0 1 (11) 1 (11) 3 (6)
O 6 (60) 4 (40) 5 (50) 5 (56) 5 (56) 25 (52)
AB 1 (10) 2 (20) 0 0 1 (11) 4 (8)
Data are given as n (percent), except for age data. Group A3 was studied in this manuscript.
doi:10.1371/journal.pmed.1001807.t002
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increases in GMFR at day 7 and day 35 after dose 1 for all GII.4 VLPs. Titers generally peaked
at day 7 post-vaccination, rising 6.2-fold for GII.4C, 5.2-fold for GII.4.1997, 5.2-fold for
GII.4.2002, and 3.3-fold for GII.4.2006b. As demonstrated for GI VLPs, despite a booster vacci-
nation at day 28, day 35 titers were lower than day 7 titers, with GMFRs of 4.5 for GII.4C, 3.9
for GII.4.1997, 3.0 for 2002, and 2.5 for GII.4.2006b. At day 180, IgG titers were less than 2-
fold above baseline for all of the GII.4 VLPs. Secretor-negative and -positive participants re-
sponded similarly to GII.4 VLPs (S1 Fig.). As individuals (S3 Fig.), at day 7, 6/10 participants
seroresponded to GII.4C, 5/10 to GII.4.1997, and 4/10 to GII.4.2002 and GII.4.2006b VLPs. At
day 35, the response rates were 7/10, 5/10, 4/10, and 1/10, respectively. At day 180, 1/9 partici-
pants maintained a seroresponse to GII.4C and GII.4.1997.
Increases in cross-reactive IgG were detected to GII.2, GII.3, and GII.14 VLPs after vaccina-
tion. As a group (Fig. 3), a4-fold increase in titer was not detected for any of the non-GII.4
GII VLPs at any time point. Some individuals did serorespond to each of the non-GII.4 GII
VLPs, although none of the responses persisted to day 180 (S3 Fig.). GMTs were not signifi-
cantly different for any non-GII.4 GII VLPs at any time point. Despite this observation,
Fig 3. Mean EC50 IgG titer in vaccinated participants. Serum samples collected from participants who received the 50/50-μg VLP dose were assayed for
IgG reactivity to a panel of GI (blue), GII.4 (grey), and non-GII.4 GII (green) VLPs. The seroresponse rate is the ratio of the number of participants with a4-
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secretor status significantly impacted the GMFRs to non-GII.4 GII VLPs. Secretor-negative
participants had significantly higher GMFRs on day 7 and 35 to GII.2, GII.3, and GII.14 (S1
Fig.). Together, these data indicate that the multivalent vaccine induces production of IgG that
reacts with not only the immunizing strain VLPs but also VLPs from strains and genotypes not
included in the vaccine. Maximum serum IgG levels were seen after a single dose of vaccine,
and serum IgG was not equally reactive with all NoV genotypes.
Vaccination with the Multivalent Virus-Like Particle Candidate Vaccine
Results in Cross-Strain Blockade Antibody Responses
The inherent cross-strain reactivity of serum IgG demonstrated above and elsewhere [19,41]
has confounded interpretation of the association between IgG and risk of NoV infection. How-
ever, the specificity of measuring blockade Abs demonstrated a clear correlation between titer
and protection both from GI.1 symptomatic infection and reinfection with homotypic virus in
challenge studies [23]. Therefore, we tested the serum samples for blockade Ab titers against
the panel of GI, GII.4, and non-GII.4 GII VLPs as a predictor of cross-strain protection after
vaccination. As a group, there were no significant differences in blockade Ab titer between any
VLP pair at day 0. Day 0 geometric mean blockade Ab titers to GI VLPs were low, with signifi-
cant increases in GMFRs at day 7 and 35 for all three GI VLPS (Fig. 4). Titers peaked at day 7
post-vaccination, rising 30.7-fold above baseline for GI.1, 7.4-fold for GI.3, and 4.1-fold for
GI.4. At day 35, GMFRs were 12.3 for GI.1, 3.1 for GI.3, and 1.5 for GI.4. Blockade Ab titers re-
turned to baseline levels at day 180. GI blockade Ab GMFRs were not dependent on secretor
status (S2 Fig.). Individually (S4 Fig.), at day 7, 9/10 participants responded with a4-fold in-
crease in blockade Ab titer to GI.1, 6/10 to GI.3, and 4/8 to GI.4. At day 35, elevated titers were
maintained in 8/10 participants to GI.1, 4/10 to GI.3, and 1/10 to GI.4. At day 180, 2/9 partici-
pants maintained a4-fold increase in blockade Ab titer to GI.1, and 1/9 to GI.3.
The nearly 100% NoV seropositivity in adults indicates wide NoV exposure across the pop-
ulation [38]. Because Ab matures through somatic hypermutation (SHM) after each additional
antigen encounter [47], we evaluated the ratio of blockade Ab to reactive IgG for each VLP as a
potential marker of the specificity and maturity of the vaccine-induced Ab response amongst
the panel of VLPs. A ratio 1 suggests that serum may have more blockade activity per IgG ac-
tivity and thus may be more mature and the result of a repeat exposure. The ratio of blockade
Ab to IgG increased*3-fold above baseline for GI.1 at day 7, while remaining unchanged for
GI.3 and GI.4 (S5 Fig.). These data suggest that vaccination may primarily induce production
of Abs with enhanced potency for GI.1 blockade, likely because of SHM of preexisting cross-GI
blockade Abs that were affinity-matured against GI.1 post-vaccine exposure, while maintaining
some fraction of cross-strain blockade Abs.
For GII.4 VLPs (Fig. 4), the day 0 geometric mean blockade Ab titers were relatively low,
with significant increases in GMFRs at day 7 for all GII.4 VLPs and at day 35 for GII.4C,
GII.4.1997, and GII.4.2006b. Blockade titers were similar across the panel of different GII.4
strains, with no significant differences in GMFR at any time point. Titers peaked at day 7 post-
vaccination, rising 32.6-fold for GII.4C, 21.7-fold for GII.4.1997, 11.6-fold for GII.4.2002, and
9.5-fold for GII.4.2006b. Day 35 GMFRs for blockade Ab titers were 7.1 for GII.4C, 4.7 for
GII.4.1997, 3.3 for GII.4.2002, and 3.8 for GII.4.2006b. At day 180, blockade Ab titers ap-
proached baseline (1.1- to 2.6-fold) for all of the GII.4 VLPs. Secretor-negative participants re-
sponded similarly to secretor-positive participants across the GII.4 panel (S2 Fig.). Individually
(S4 Fig.), 8/10 participants responded with a4-fold increase in blockade Ab titer to GII.4C at
day 7 and day 35. At day 180,4-fold titers were maintained in 2/9 of the participants. Similar
high levels of fold increase above baseline blockade Ab titer extended across the GII.4 panel at
Norovirus Vaccine Cross-Blockade
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day 7 (GII.4.1997 and GII.4.2002, 8/10; GII.4.2006b, 6/10). By day 35, 4/10 of participants
maintained titers4-fold above baseline for GII.4.1997, GII.4.2002, and GII.4.2006b. At day
180, 2/9 participants sustained4-fold titers to GII.4.1997, and 1/9 participants to
GII.4.2006b. Notably, the ratio of blockade Ab to IgG at day 7 compared to the baseline ratio
increased for all GII.4 VLPs (fold increase: GII.4C, 5.2; GII.4.1997, 4.1; GII.4.2002, 2.2;
Fig 4. Mean EC50 blockade antibody titer in vaccinated participants. Serum samples collected from participants who received the 50/50-μg VLP dose
were assayed for blockade Ab to a panel of GI (blue), GII.4 (grey), and non-GII.4 GII (green) VLPs. The seroresponse rate is the ratio of the number of
participants with a4-fold titer increase above day 0 titer compared to the total number of samples tested at day 0 for each VLP. Bolded values denote
significant increases in GMFR above baseline.
doi:10.1371/journal.pmed.1001807.g004
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GII.4.2006b, 2.9) (S5 Fig.), suggesting that vaccination induces a broad GII.4-reactive response
despite strain evolution over the 15-y period represented in the panel.
Baseline blockade Ab titers to GII.3 and GII.14 non-vaccine types were low and had signifi-
cant increases in GMFR only on day 7. As a group (Fig. 4), titers peaked at day 7 at 5.5-fold
(GII.3) and 14.3-fold (GII.14) above baseline. Elevated blockade Ab titers were not boosted or
maintained at day 35 or 180, although some individuals did maintain4-fold increases at
these later time points (S4 Fig.). Contrary to IgG findings, secretor-negative status did not asso-
ciate with higher GMFR in blockade Ab titer post-vaccination (S2 Fig.). The ratio of blockade
Ab to IgG increased for both VLPs at day 7 compared to day 0 (fold increase: GII.3, 3.1; GII.14,
6.8) (S5 Fig.) before returning to baseline ratios, supporting GII.4 VLP data indicating that vac-
cination induces a rapid, broad GII Ab response.
Elevated Preexisting Blockade Antibody Titers against Any Norovirus
Virus-Like Particles Do Not Prevent a Vaccine Response
Preexisting blockade Ab titers have been shown to correlate with protection from GI.1 infec-
tion and illness in a NoV challenge study [23]; however, the effect of preexisting Ab on vaccine
response is unknown. The absence of a titer boost after the second vaccine dose suggests that
preexisting Ab titers may have a limiting effect on the magnitude of subsequent vaccine re-
sponses or that vaccine-induced Ab titers plateau [37,42]. To determine whether elevated
blockade Ab titer in the 50-μg dose group may have impacted the multivalent VLP vaccine re-
sponse, we evaluated the association between day 0 blockade Ab titers to any of the NoV VLPs
and the likelihood of developing a4-fold increase in blockade Ab titer. The lack of preexisting
blockade Ab to any NoV VLP tested significantly correlated with increased vaccine response
by day 7 (p< 0.001, chi-squared test) (Fig. 5A). Independent of VLP tested, 51 out of 57
(89.5%) samples with a4-fold increase in blockade Ab titer post-vaccination had no detect-
able VLP-specific blockade Ab titer at day 0. Sera with baseline blockade Ab titer below the
limit of detection were 2.6 (excluding vaccine VLP responses for the analysis) or 3.1 times (in-
cluding all VLPs) more likely to have a4-fold increase in blockade Ab titer to the same VLP
Fig 5. Day 0 blockade antibody titers below the assay limit of detection for any norovirus virus-like particle are predictive of a4-fold increase, but
not overall blockade Ab titer, at day 7. Day 0 blockade Ab titers for all of the NoV VLPs studied were compared to the corresponding day 7 fold increase (A)
and titer of blockade Ab (B) using GEEs (n = 10 participants, 82 samples). The likelihood of responding to vaccination with a4-fold increase in blockade Ab
titer to any NoV VLP was 3-fold greater if the day 0 titer was below the assay limit of detection. Day 0 blockade Ab titer did not correspond with day 7 titer. The
dotted lines mark the lower limit of detection of the blockade Ab assay. The solid grey line marks a 4-fold increase in blockade titer at day 7. RR, relative risk.
doi:10.1371/journal.pmed.1001807.g005
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at day 7 post-vaccination compared to participants with higher blockade Ab titers. However,
further analyses of the relationship between day 0 blockade Ab titers and day 7 titers revealed
no significant association (Fig. 5B), regardless of inclusion of vaccine VLP responses, as partici-
pants with higher baseline titers also responded with an increase in titer of4-fold at day 7.
Together these data show that the presence of preexisting blockade Ab does not prevent a NoV
blockade Ab response to vaccination, but instead that an Ab titer plateau can be reached re-
gardless of baseline titer.
Vaccination with the Multivalent Virus-Like Particle Candidate Vaccine
Induces Antibody That Blocks Novel GII.4 Norovirus Strain Virus-Like
Particles
The data described above clearly indicate that vaccination induces a boost in blockade Ab
across GII.4 VLPs that circulated before the vaccination program. To evaluate Ab activity
against a newly emergent GII.4 strain for which preexisting immunity is unlikely, we tested the
serum samples for reactive IgG and blockade Ab titer against two novel GII.4 strain VLPs
(Figs. 1 and 6–8). GII.4.2012 began circulating globally in 2012, more than a year after the trial
sample collection was completed. GII.4.2006b.P.D302 VLP represents a unique GII.4 strain se-
quenced from an immune-compromised patient with symptomatic NoV infection for over 1 y
[45,48]. Importantly, GII.4.2006b.P.D302 is divergent from GII.4.2006b at all three evolving
blockade epitopes, resulting in loss of Ab blocking activity of mouse and human polyclonal
sera and mAbs (Fig. 8 and [45]). As the extensive cross-reactivity studies described above had
depleted the finite volume of each serum sample that had been set aside for these exploratory
Fig 6. Mean EC50 IgG titers to novel GII.4 strain virus-like particles. Serum samples collected from participants who received the 50/50-μg VLP dose
were assayed for IgG reactivity to the vaccine components and to two novel GII.4 VLPs. GI VLP is shaded blue; GII.4 VLPs are shaded grey. The
seroresponse rate is the ratio of the number of participants with a4-fold titer increase above day 0 titer compared to the total number of samples tested at
day 0 for each VLP. Bolded values denote significant increases in GMFR above baseline.
doi:10.1371/journal.pmed.1001807.g006
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studies, we included day 21 serum samples from the same participants in the novel GII.4 VLP
studies. Consequently, responses to the novel GII.4 VLPs are likely impacted by sample num-
ber loss due to volume depletion (Figs. 6, 7, and S1–S4). Similar to the titers for the other GII.4
strains, baseline reactive IgG GMTs to GII.4.2012 and GII.4.2006b.P.D302 were relatively low,
with significant increases in GMFRs at day 7, 21, 35, and 180 to GII.4.2012 (Fig. 6). GII.4.2012
titers peaked at 4.1-fold on day 7, followed by 2.8-fold at day 21, 2.3-fold at day 35, and 1.5-
fold at day 180 after dose 1. IgG GMFRs to both novel GII.4 VLPs were similar between secre-
tor-negative and -positive participants (S1 Fig.) Individually, GII.4.2012 seroresponse rates
were 3/7 at day 7, 1/9 at day 21, 2/9 at day 35, and 0/7 at day 180 (S3 Fig.). IgG GMFRs to
GII.4.2006b.P.D302 were significant on day 7, 21, and 35, rising 2.2-, 2.2-, and 2.0-fold, respec-
tively. Unlike for the other VLPs tested, GII.4.2006b.P.D302 IgG titers did not change4-fold
with vaccination at any time point (Figs. 6 and S3).
Fig 7. Mean EC50 blockade antibody titers to novel GII.4 strain virus-like particles. Serum samples collected from participants who received the 50/50-μg
VLP dose were assayed for blockade Ab to the vaccine components and to two novel GII.4 VLPs. GI VLP is shaded blue; GII.4 VLPs are shaded grey. The
seroresponse rate is the ratio of the number of participants with a4-fold titer increase above day 0 titer compared to the total number of samples tested at day 0
for each VLP. Bolded values denote significant increases in GMFR above baseline.
doi:10.1371/journal.pmed.1001807.g007
Fig 8. Amino acid sequence of identified GII.4 blockade antibody epitopes (A, D, and E) and the regulating domain of epitope F (NERKmotif) in
GII.4 virus-like particles relevant to this study.Color indicates antigenic groupings based on epitope A sequence. *The amino acid coordinates of epitope
F are unknown. The NERKmotif is a temperature-sensitive regulator of Ab access to epitope F [32].
doi:10.1371/journal.pmed.1001807.g008
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Similar to IgG titers, as a group, day 0 geometric mean blockade Ab titers against both novel
GII.4 VLPs were low, with significant increases in GMFR on day 7, 21, and 35 for GII.4.2012
(Fig. 7). GII.4.2012 titers peaked at day 7 post-vaccination, rising 13.4-fold, followed by 9.8-fold
on day 21 and 3.2-fold on day 35, before returning to baseline on day 180. Blockade Ab GMFRs
to both novel GII.4 VLPs were similar between secretor-negative and -positive participants (S2
Fig.). Individually (S4 Fig.), 4/7 participants had a4-fold increase in blockade Ab titer to
GII.4.2012 at day 7, 6/10 at day 21, 4/10 at day 35, and 1/8 at day 180. GII.4.2006b.P.D302 titers
peaked at day 21 at 17.0-fold above baseline. Day 35 titers were 3.9-fold above baseline. The lack
of significant response at day 7 and day 35 is likely impacted by additional sample depletion
(Figs. 7, S2, and S4). At day 180, blockade Ab titers had returned to near baseline. Individually
(S4 Fig.), 3/5 participants had a4-fold increase in blockade Ab titer to GII.4.2006b.P.D302 at
day 7, 7/8 at day 21, 3/6 at day 35, and 1/7 at day 180. The ratio of blockade Ab to IgG increased
for both VLPs at day 7 compared to day 0 (S5 Fig.) before returning to baseline ratios. As identi-
fied for the other GII.4 VLPs, the ratio of blockade Ab to IgG was greater than one through day
35, indicating that the GII.4.2012 and GII.4.2006b.P.D302 blockade Ab may be mature Ab de-
rived from previous NoV exposures. Importantly, these data demonstrate that NoVmultivalent
VLP vaccination can induce a blockade Ab response to a GII.4 strain unknown at the time of
vaccination, suggesting that broad-based NoV immunity by vaccination is an achievable goal.
Multivalent Virus-Like Particle Vaccine-Induced Antibody Responses
Associate with Antibody Responses to Early (1997–2002) GII.4 Strains
To test for any relationship between the vaccine components and other NoV VLPs that may be
indicative of shared epitopes, we first compared the antigenic relationship of the panel of NoV
VLPs based on IgG reactivity and blockade Ab titer using MDS computational and statistical
approaches. These approaches are a powerful tool to help visualize and analyze similarities be-
tween samples across a range of variables, in this case, analyzing the similarities between differ-
ent VLPs (samples) based on their likelihood of an immune response being raised across a
range of individuals (variables). In order to assess the overall similarities that pairs of VLPs ex-
hibited across sera from vaccinated individuals, we calculated Euclidean distances, D (see S1
Table), between each VLP pair at each time point. Euclidean distances are calculated such that
two VLPs possessing identical EC50 values for each tested serum will have a D of 0; with in-
creasing dissimilarity in the responses these VLPs share within any specific sera, D will in-
crease. In our analysis of IgG similarities, each D unit equaled roughly a 3.4-fold difference in
overall serum response. We utilized MDS to identify XYZ coordinates for each VLP that accu-
rately capture the D values between VLPs, as described previously [46,49]. This approach al-
lowed us to visualize and analyze the cross-reactivity of the IgG response over the time course
of this study (Fig. 9).
At day 0 before vaccination, the NoV VLPs were generally clustered together and did not
sort by subtypes (GI versus early GII.4 [1997 and 2002] versus late GII.4 [2006b and 2012] ver-
sus other GII genotype VLPs; Fig. 9A–C), with the average D between VLPs being 1.79 (range
0.55–3.34). At day 7, the peak of vaccine response (Fig. 9D–F), the distance between VLPs ex-
panded, with an average D of 3.07 (range 1.12–4.89), illustrating the fact that individual vaccine
recipients mounted responses to aspects of the vaccine, but that these responses were not uni-
versal across VLPs (if this were the case, all VLPs would still remain closely clustered), specifi-
cally when examining VLPs not included in the vaccine formulation. As could be seen when
examining the primary IgG response to GI.1, there was a distinct response to this vaccine com-
ponent. Utilization of antigenic cartography allowed us to show that the responses to this VLP
were quite distinct from those raised against other VLPs. In particular, the D values between
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GI.1 and all GII viruses (average D = 3.79, range 3.0–4.24) show that the response raised
against the GI.1 component of the vaccine was fairly independent of the responses raised
against GII VLPs. While not attaining multiple-test-correcting significance (t25 = 4.795, p =
0.038), the effect of cross-reactivity between GI.1 and the other GI VLPs was apparent in our
analysis. These VLPs are individually fairly distant from GI.1 (D of 3.4 and 2.7), but as a trio
they segregate away from the GII VLPs (average D = 3.59, range 2.24–4.56). This result illus-
trates our ability to detect even weak secondary responses against these dissimilar GI VLPs by
utilizing antigenic cartographic approaches.
As described above, GII VLPs were distinct from the GI VLPs at 7 d post-vaccination. Inter-
estingly, the GII.4C VLP (representing the vaccine component) associated much more closely
with the early GII.4 VLPs than with either the late GII.4 VLPs or the GII VLPs from other ge-
notypes (ANOVA: F2,4 = 14.74, p = 0.0143), showing that the IgG response to GII.4C vaccina-
tion is highly cross-reactive with the early GII.4 VLPs but not the antigenically distinct
contemporary GII.4 VLPs or other GII VLPs. Even as late as 180 d post-vaccination (Fig. 9G–
I), clustering by genogroup (or by subclades within genogroups) remained (t-test: t53 = 23.96,
p< 0.001), although overall distances (dissimilarities) in IgG responses differentiating between
VLPs had decreased compared to day 7. Specifically, the GI viruses clustered relative to the
Fig 9. Evolving IgG responses to virus-like particles throughout the time course of the study. Individual points represent VLPs, and the distances
between points represent the overall differences in the magnitude of IgG responses from all ten participants against these NoV VLPs on day 0 (A–C), day 7
(D–F), and day 180 (G–I). Specifically, the distance between VLPs (with each unit in any dimension [D] relating to a 3.4-fold difference in total IgG responses)
shows how similar total IgG responses across the ten participants were to each pair of VLPs tested within this study and how vaccine components (noted in
each panel) cluster with other NoV strain VLPs. Despite similarities across these responses, we are able to show that GI VLPs (orange) cluster with the GI.1
vaccine component, early GII.4 VLPs (blue) cluster with the GII.4C vaccine component, and late GII.4 VLPs (green) and the other GII VLPs (pink) cluster
together and away from the other VLPs. For each time point, the x-axis is that showing the most variation between all VLPs, then the y-axis, then the z-axis.
Therefore, down each column, we can see how immune responses change and track through the time course of the study. Of note are the clusterings of each
virus subtype through these responses.
doi:10.1371/journal.pmed.1001807.g009
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other virus strains (t25 = 11.32, p = 0.0024), GII.4C continued to cluster with GII.4.1997 and
GII.4.2002 (t25 = 8.973, p = 0.0061), and the contemporary GII.4 VLPs remained tightly clus-
tered with the other GII genotypes (t38 = 19.24, p< 0.001). Interestingly, and echoing our find-
ings above, GII.4.1997 remained somewhat distinct from GII.4C and GII.4.2002 (Fig. 9G–I)
because of the elevated levels of IgG against GII.4.1997 VLP still found in several of the vaccine
recipients 6 mo post-vaccination.
Similar analyses using blockade Ab titers rather than IgG titers supported several of these
findings, with the D values calculated for blockade titers corresponding to roughly a 3.2-fold
change in blockade levels. In contrast to the tight clustering of VLPs in the EIA-reactive IgG be-
fore vaccination, the spread of the distances between VLPs was greater (average D = 2.88,
range 0–4.52), indicative of the strain specificity of blockade Ab as well as the individual-to-in-
dividual variation in pre-immunization blockade levels (Fig. 10). There was some limited
cross-reactivity even at day 0 (Fig. 10A–C), with subtypes being significantly more related than
genotypes (t43 = 11.99, p = 0.001; within-subtype average D = 1.77, range 0–2.79; between-sub-
type average D = 3.13, range 0.77–4.52).
Fig 10. Evolving blockade antibody responses to virus-like particles throughout the time course of the study. Individual points represent VLPs, and
the distances between points represent the overall differences in the magnitude of blockade Ab responses from all ten participants against these NoV VLPs
on day 0 (A–C), day 7 (D–F), and day 180 (G–I). Specifically, the distance between VLPs (with each unit in any dimension [D] relating to a 3.2-fold difference
in blockade Ab, or EC50 response) shows how similar total blockade Ab responses across the ten participants were between each pair of VLPs tested within
this study, and how vaccine components (noted in each panel) cluster with other NoV strain VLPs. Across these responses, we are able to show that GI
VLPs (orange) cluster with the GI.1 vaccine component, early GII.4 VLPs (blue) cluster with the GII.4C vaccine component, and the late GII.4 VLPs (green)
and the other GII VLPs (pink) cluster together and away from the other VLPs. For each time point, the x-axis is that showing the most variation between all
VLPs, then the y-axis, then the z-axis. Therefore, down each column, we can see how immune responses change and track through the time course of the
study. Of note are the clusterings of each virus subtype through time, although with clear distinction of the vaccine components at day 7. At day 180, as titers
have fallen, the blockade Ab distinctions between VLPs are diminished across the panels (G–I), with the exception of responses to GII.4.1997, suggesting
that a memory Ab response to this strain may be driving the GII.4-reactive vaccine response.
doi:10.1371/journal.pmed.1001807.g010
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At 7 d post-vaccination (Fig. 10D–F), there was a wider range of D values (average D = 5.43,
range 1.86–10.10). There was still a significant relationship between subtypes (t43 = 9.327, p =
0.0039), although the strong participant-specific responses to some VLPs obscured some of
these groupings. Genotype grouping could not be definitively assigned to any given vaccine re-
sponses, as the GI VLPs remained only moderately clustered together (t22 = 7.517, p = 0.011;
multiple-test cutoff is p = 0.0166), and while the GII VLPs clustered together (t40 = 40.11, p<
0.001), the GII.4C VLP did not cluster with any given GII subgroup. Consistent with our other
observations above, while we cannot assign statistical confidence to this observation (as there is
only a single D value to contrast), the two vaccine components (GI.1 and GII.4C) appeared to
slightly co-segregate within the three-dimensional space (Fig. 10D–F), corresponding to the
strong vaccine responses driven across vaccine recipients.
At day 180 (Fig. 10G–I), the distance between VLP clusters decreased (average D = 3.07,
range 1.19–6.57), but was still elevated relative to pre-vaccine levels. In contrast to other time
points, there was only a very moderate subgroup-based clustering (t43 = 4.277, p = 0.045),
which could not be attributed to any given subgroup. Most of the variation within these re-
sponses is due to the maintenance of blockade Ab to GII.4.1997 VLP (t43 = 29.8, p< 0.001).
These data support our premise that the GI.1 response can be characterized as an immature Ab
response while the GII.4C response can be characterized as a memory Ab response driven by
Abs that react primarily with epitopes present in GII.4.1997. We arrive at this conclusion spe-
cifically because blockade Ab responses are much stronger for GII.4.1997 than even for the vac-
cine component GII.4C.
Vaccination with the Multivalent Virus-Like Particle Candidate Vaccine
Induces Blockade Antibody Responses to Multiple Epitopes Cross-
Reactive between Antigenically Divergent GII.4 Virus-Like Particles
To expand on the antigenic cartography findings identifying Abs to GII.4.1997 as key driving
components of the vaccine-induced Ab response, we then asked whether the GII.4 Ab response
generated after vaccination could be explained by activation of Abs to known GII.4 blockade
epitopes A or F. We evaluated the ability of day 0, 7, 35, and 180 serum samples to block bind-
ing of mAbs to highly variable, surface-exposed blockade epitope A and sub-surface, conserved
blockade epitope F using the blocking of binding (BOB) assay and GII.4.1997 and GII.4.2006b
VLPs. GII.4.1997 and GII.4.2006b are antigenically distinct at evolving blockade epitope A
(Fig. 8). Mouse mAb GII.4.1987.G1 and GII.4.2006.G2 [27] recognize epitope A of GII.4.1997
and GII.4.2006b, respectively. Mouse mAb GII.4.2002.G5 [32] recognizes the epitope F con-
served among the GII.4 types. All serum samples remaining were tested for BOB. Pre-vaccina-
tion sera (n = 9) did not block binding of mAbs to epitope A or to epitope F to either VLP
(Fig. 11). At day 7 (n = 7), significant broad BOB of epitope A and F mAbs was observed for
both GII.4.1997 and GII.4.2006b, with significantly higher levels of inhibition noted against the
GII.4.1997 strain for both epitopes (epitope A, 7-fold higher; epitope F, 5-fold higher). By day
35 (n = 8), significantly higher BOB titers to only epitope A of both strains remained. At day
180, titers (n = 8) to GII.4.1997 epitope A persisted but at levels not significantly different from
baseline titers. These findings support the antigenic cartography analyses indicating that Ab to
structures present in GII.4.1997 may be more persistent than Ab to other structures. Further, it
suggests that the broad cross-reactive GII.4 Ab response targets residues either within, near, or
regulating access to multiple epitopes, including epitopes A and F.
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Discussion
The success of the rotavirus vaccination campaign has elevated NoV to the main cause of acute
viral gastroenteritis in infants and young children in the US and elsewhere, and, subsequently,
has focused attention on the development of a NoV vaccine (reviewed in [36,50]). Here we pro-
vide evidence that a NoV VLP-based vaccine induced broadly reactive IgG and blockade Ab re-
sponses among antigenically diverse NoV VLPs, as has been shown for mice immunized with a
multivalent NoV VLP vaccine [44] and humans infected with GI.1 [51]. Ab cross-reactivity in-
cluded two GII.4 VLPs representing viral strains that did not circulate within the population
before the study sample collection was completed, indicating that vaccination may protect
against emergent GII.4 strains that are antigenically distinct from the vaccine components.
As NoV strains share common Ab epitopes, the Ab detection assays utilized here were opti-
mized for specificity by limiting the amount of antigen. This approach allows detection of sub-
tle differences in Ab affinities between closely related strains but decreases assay sensitivity,
resulting in more samples registering below the limit of detection. Similarly, the high valency
of PGM facilitates binding of many diverse NoV VLPs to a single, readily available substrate
but also translates to increased serum titers needed for Ab blockade of VLP–ligand binding
compared to the less valent synthetic carbohydrates frequently used [25,29]. Consequently, the
magnitude and duration of Ab responses (GMTs and GMFRs) in these analyses were lower
than those reported by other vaccine investigations, which used*10× more antigen in Ab de-
tection assays and synthetic carbohydrates for blockade Ab assays [37]. The limiting amount of
Fig 11. Vaccination results in a rapid but transient increase in antibody titer to multiple blockade
epitopes in multiple GII.4 strains. Serum samples were evaluated for ability to block binding of mouse
mAbs to epitope (Epi) A or F in GII.4.1997 and GII.4.2006b using a BOB assay. Sigmoidal curves were fit to
the mean percent control binding (percent of mouse mAb bound to VLP in the presence of serum
pretreatment compared to the amount of mouse mAb bound in the absence of serum pretreatment), and the
mean EC50 titer (1/serum dilution) for BOB calculated. Dotted line marks 0.5 times the assay limit of
detection. Error bars represent 95% confidence intervals. An asterisk indicates that the EC50 titer is
significantly different from that of day 0.
doi:10.1371/journal.pmed.1001807.g011
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antigen likely also caused underestimation of the baseline differences between participants of
secretor-negative and -positive phenotypes. Further, the VLPs used here, except GII.4C, were
produced at 37°C from mammalian cell expression vectors, whereas the GII.4C VLPs and the
vaccine VLPs were produced at a lower temperature in insect cells. How these differences in
VLP production might affect particle structure and Ab binding is unclear, but antigenic differ-
ences have been described between NoV VLPs manufactured in the two different expression
systems [32].
Pre-exposure history likely shaped the breadth and magnitude of the vaccine-induced
blockade Ab cross-reactivity. Although a secretor-negative phenotype is associated with de-
creased risk of infection with some NoV strains [18,40], secretor status was not a primary driv-
er of vaccine response, as secretor-negative participants responded similarly to secretor-
positive participants for blockade Ab to the entire panel of VLPs, in concordance with in vitro
[38] and in vivo [39–41] data indicating that some GI and GII NoV strains bind to secretor-
negative carbohydrates and infect secretor-negative individuals. Further, as GII.4 strains com-
monly circulate, it is likely that participants in the study have a recent exposure history to
GII.4, and this may have influenced the characteristics of the vaccine response. The increased
ratio of blockade Ab to EIA-reactive IgG across GII.4 VLPs suggests that, likely as a result of
previous exposure to GII.4 strains through natural infection, the GII.4C vaccine component re-
sponse may be driven by activation of preexisting, cross-reactive memory B cells, as has been
described for broadly neutralizing influenza Ab [52,53], while the GI.1 response may be driven
by SHM and expansion of more strain-specific B cells (Fig. 12). Higher preexisting blockade
Ab titers did not interfere with additional Ab production, but individuals with higher baseline
titers tended to have lower fold increases, which may be indicative of a ceiling for maximum re-
sponses, as described for measles virus vector and some influenza A vaccinations [54,55]. Simi-
larly, lack of an additional titer boost after a second vaccination<1 mo later is documented for
influenza vaccinations, where the vaccine regimen achieves high levels of seroresponse and ser-
oprotection (hemagglutination inhibition> 40) after only one dose [56,57], indicating that
higher Ab titers correlate with a lower magnitude of response but not necessarily less protec-
tion from infection. Of note, in the influenza studies cited above, children and older adults had
better Ab responses after two vaccine doses. Given that both of these demographics would be
key candidates for a NoV vaccine, follow-up studies of different age cohorts will be necessary
and are ongoing. Such studies will specifically address the kinetics and breadth of the blockade
Ab response in children and may clarify the relationship between pre-exposure history and
vaccination response.
At day 7 post-vaccination, Ab titers peak in magnitude and breadth of reactivity, corre-
sponding with the timing of an expanded B cell clonal population [58]. This broad reactivity
may be the result of the multivalency of the VLP vaccine, epitope presentation on a VLP com-
pared to natural virus, or the difference in dose or route of antigen delivered by vaccination
versus infection. Alternatively, it is possible that a broad blockade Ab response also occurs after
natural infection at day 7, as this has not been tested. Although vaccination induced homotypic
serum Ab responses at levels similar to or higher than natural infection in a challenge study
[42], titers did not boost after a second immunization, agreeing with our findings. These data
suggest one vaccine dose may induce maximum responses. Although, mechanistically, it is un-
clear why this would be the case in participants with lower preexisting titers, these findings
may indicate that for the age group 18–49 y (characterized by extensive previous exposure his-
tory), more time may be needed between the first and second vaccination to allow titers to re-
turn to baseline and the Ab pool to mature and develop higher affinities. Alternately, serum
titers may be decreasing because ASCs may be relocating to the mucosal induction sites (e.g.,
Peyer’s patches in the intestine), with a resulting boost in a responder B cell population at the
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site of future exposure to NoV. B cell and ASC migration to the gut has been shown to be criti-
cal for conferring protection against intestinal pathogens [59], and memory B cells from beta-
7-integrin-deficient mice have been shown to exhibit a decreased capacity to protect against ro-
tavirus infections, implying that gut homing plays an important role in protection against in-
testinal viruses [60]. To understand NoV immunity and protection from infection, direct
measurement of mucosal Ab responses is needed, as mucosal IgA responses have been shown
to correlate with protection in GI.1 virus challenge [18]. Challenge studies in vaccinated and
non-vaccinated participants need to be done to address these fundamental questions.
The technique of antigenic cartography has been implemented by theWorld Health Organi-
zation to track influenza [49], as the power of cartography in sorting antigenic variants has
been demonstrated for influenza [61], enterovirus [62], and NoV [63]. This technique has typi-
cally been used to assess the general relationships between variant viruses, using hyperimmune
sera to assess antigenic similarities. Here we have slightly modified this approach to utilize vari-
ant viruses as probes to disentangle the complex immune responses following vaccination,
while maintaining a well-developed analytical framework. This approach recapitulated many
of the findings observed by our more traditional analyses of immune responses, and also al-
lowed us to identify several more subtle differences in immune responses across this popula-
tion of vaccine recipients. Here, IgG and blockade Ab responses to GI.1 are less distant from
those to other GI VLPs compared to those to non-GI VLPs, but remain clearly separate from
responses to GI.3 and GI.4. In contrast, IgG and blockade Ab responses cluster GII.4C close to
the other GII.4 VLPs, while the distance between GII.4C and the other GII VLPs is greater. The
distance, and thus antigenic divergence, between GII.4C and GII.4.1997 and GII.4.2002 is rela-
tively close at day 7. By day 180, GII.4C and GII.4.2002 associate very closely with each other
and cluster more closely to the other VLPs, and only GII.4.1997 remains distinct.
The strength of the blockade Ab response to GII.4.1997 and degree of cross-blockade
among GII.4 VLPs is contrary to findings with mAbs and polyclonal serum collected from out-
breaks and immunized mice. Pandemic GII.4 strains can be considered successive immune es-
cape variants. The GII.4 VLPs studied here represent the antigenic diversity of the GII.4
outbreak strains that have circulated worldwide from 1995 to the present. Using human out-
break and immunized-mouse polyclonal sera, GII.4.1997 and GII.4.2002 have some cross-
blockade activity between them and are each distinct from GII.4C at the identified GII.4 evolv-
ing blockade epitopes A, D, and E. However, GII.4.1997, GII.4.2002, and GII.4C are all blocked
by mAbs that recognize epitope F, a conserved GII.4 blockade epitope [25,32], indicating a pos-
sible mechanism for cross-GII.4 blockade Ab activity, despite antigenic drift within the
GII.4 strains.
Fig 12. Proposedmechanisms for antibody responses induced by GI.1/GII.4Cmultivalent vaccine. At the time of vaccination, adult participants have a
lifetime of NoV exposure history and a pool of NoV-reactive memory B cells (Bmem cells), both strain-specific and strain cross-reactive clones. Vaccination
activates memory B cells to undergo SHM of the variable region of the Ab gene, to proliferate, and, for some cells, to differentiate into plasma cells secreting
high-affinity Ab by day 7 post-vaccination. The GI.1 vaccine component elicits activation of both GI.1-specific memory B cells and memory B cells with
specificity for shared GI epitopes, resulting in increased Ab to the panel of GI VLPs, but the strongest response to the homotypic GI.1 VLP because more
blockade epitopes are unique to GI.1 than are shared across the GI VLPs. By day 180, low levels of GI.1-specific Ab persist (A). In comparison, the GII.4C
vaccine component does not elicit a strong strain-specific response but could in theory activate memory B cells with GII.4.2002, GII.4.2006a, or GII.4.2006b
specificity. However, the uniformity in the GII.4 VLP response across an antigenically diverse panel suggests that GII.4C preferentially activates memory B
cells for conserved GII.4 epitopes and a smaller subset of memory B cells for a conserved GII epitope, resulting in more potent GII.4 and less potent GII
blockade Ab production at day 7. The GII.4C Ab response continues to track with GII.4.2002 and GII.4.1997 through day 35, but by day 180, only GII.4.1997
Ab responses remain distinct, suggesting that the commonGII.4 blockade epitopes recognized by the vaccine-induced Abs are most similar to sequences
found in GII.4.1997, possibly because of extensive long-term immune focusing for this strain. Ab responses to at least two epitopes are maintained. Epitope F
is a conserved GII.4 blockade epitope located sub-surface on the particle, and proposed epitope A0 is likely a surface-exposed blockade epitope physically
near, overlapping, or within epitope A (B).
doi:10.1371/journal.pmed.1001807.g012
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Vaccination did lead to increased titers of Ab that interfered with binding of epitope F mAb
to GII.4.1997 and GII.4.2006b, as measured by the BOB assay, supporting activation of cross-
GII.4 memory B cells with vaccination. Epitope F is conserved but not identical within the
GII.4 strains [25], explaining the difference in epitope F BOB potency between GII.4.1997 and
GII.4.2006b. Epitope A is highly divergent between pandemic GII.4 strains; thus, it was an un-
likely candidate to explain the broad GII.4 blockade Ab response identified here. However,
minimizing steric hindrance as the explanation for these results, binding of mAb to epitope F
or epitope A did not interfere with subsequent binding of the reciprocal epitope mAb to the
immobilized VLP, indicating that Ab binding to one epitope does not necessarily prevent Ab
binding at a second epitope [32,64].
Alternatively, the serum BOB to epitope A could be mediated by a rare class of cross-reac-
tive epitope A Abs that are expressed post-vaccination because of the novel antigen that GII.4C
represents. Because epitope A is the immunodominant epitope, NoV memory B cells should be
numerically dominated by epitope A clones. If, as a chimeric-designed VLP, GII.4C has a
unique epitope A, then vaccination could preferentially select for clones that recognize a con-
served set of residues that are either part of epitope A or structurally near epitope A but are as
yet undefined. Despite significant change within epitope A between GII.4 strains, epitope A
does have a linear, conserved stretch of amino acids with demonstrated cross-GII.4 EIA bind-
ing with select mAbs [20,27], providing mechanistic support for the possibility of a broadly re-
active GII.4 epitope A Ab response. Additional conserved epitope A residues may be identified
as more mAbs are developed. The high degree of cross-GII.4 reactivity prevented us from
using epitope-exchanged VLPs to specifically map GII.4 epitopes, as we have successfully done
with mAbs and sera from infected individuals [25,27].
Both epitope mapping and antigenic cartography identified persistent responses to
GII.4.1997, the first known pandemic NoV strain, after vaccination. As all study participants
were at least 18 y old, it is highly likely that they were exposed to this first pandemic strain and
retained memory B cells from that exposure. The preferential recall Ab response to GII.4.1997
after vaccination with an antigenically distinct VLP, coupled with lower Ab titers to the most
recent pandemic strain, GII.4.2006b, all in the context of a broad cross-GII.4 blockade Ab re-
sponse, suggests that the vaccine targets memory B cells specific for conserved epitopes that
originally derived from naïve B cells specific for GII.4.1997 and were subsequently refined by
SHM following repeated NoV exposure (Fig. 12). This response pattern, termed “antigenic se-
niority” has also been identified in influenza vaccinated participants [65]. Like original antigen-
ic sin (OAS), the theory of antigenic seniority predicts that the highest affinity Ab responses
will be to the strain primarily circulating during participants’ childhoods and that this first en-
counter will shape all immune responses to viral variants going forward. With each subsequent
virus exposure, memory B cells undergo further maturation. Unlike OAS, antigenic seniority
doesn’t predict that responses to the current virus will be negated by the response to the first
virus, but instead that the Ab response will be lower in affinity for the most recent variant. Al-
ternatively, vaccination, as opposed to infection, may produce Ab to conserved epitopes that ei-
ther have a greater affinity for the epitope as it is presented in GII.4.1997 or have better access
to the epitope in GII.4.1997. If this is true, titers to GII.4.1997 would predominate and may de-
fine the Ab response maximum described. It remains to be seen whether these same Ab re-
sponse patterns develop with virus challenge. Sequencing and cloning of human Ab repertoires
at pre-vaccination and early and late post-vaccination time points, coupled with investigation
of the structures of Ab-bound VLPs, would directly address how the Ab response evolves. We
further note that we did not see preferred recall of non-vaccine-strain responses to the rarely
circulating GI NoVs. While this may be due to the overall similarities within the GI or the GII
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clusters, our expectation is that completely naïve immune responses should most match the
GI.1 or GII.4C vaccine components, and not a non-vaccine-component VLP.
The primary limitation of this study is the incomplete understanding of the relationship be-
tween the in vitro blockade Ab assay and protection from infection and illness. In a vaccine
challenge study with a GII.4.2002 challenge virus, vaccination did not significantly protect
from infection, although participant-reported gastroenteritis symptoms were reduced and
symptom severity was decreased. It is difficult to compare these findings to our prediction of
potential cross-protection based on blockade Ab response because blockade Ab titers were not
reported for those participants [42]. Further, the limited-antigen design of our experiments
complicates prediction of protection from infection and understanding of the implications of
the lack of titer boost after the second dose and rapid waning of the Ab titer. The diversity of
the VLP panel studied is not all-inclusive, as new NoV strains are regularly identified from out-
break investigations. The VLPs used here were selected for their epidemiological importance,
antigenic divergence, and availability. Although we cannot discount that Ab responses to addi-
tional genotypes may have been identified with a larger VLP panel, to our knowledge, this
study characterizes blockade Ab responses to the most antigenically diverse panel of VLPs to
date. Furthermore, our work here highlights in many ways the complex interactions between
prior exposure, each participant’s ability to respond to variable vaccine components, and the
relationships between tested VLPs. Future work assessing the impact of all of these variables
will assist in the rational design of vaccines. Despite these limitations, we were able to utilize
our molecular, immunological, and computational approaches to identify several important re-
sponses to NoV vaccination that allowed for cross-reactivity to other VLPs.
To be effective, any NoV vaccine must induce a protective immune response to novel, epi-
tope-evolved GII.4 viruses. The data presented here suggest that the GII.4C vaccine component
Ab response is likely driven by activation of preexisting cross-reactive memory B cells, resulting
in cross-blockade Ab production and potential protection from new GII.4 strains not included
in the vaccine. Given the considerable disease burden globally, these results provide sufficient
optimism for continued human studies and vaccine development.
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Editors' Summary
Background
Worldwide, noroviruses cause one in five cases of viral gastroenteritis (often called stom-
ach flu or winter vomiting disease), the symptoms of which include nausea, vomiting, and
diarrhea. There is no specific treatment for infection with these highly contagious viruses,
and no established approach to vaccine development. While most people recover from the
symptoms of norovirus infection within a few days, young children and the elderly may
become severely ill or die. An estimated annual 300 million cases of norovirus infection
contribute to roughly 260,000 deaths, mostly among this vulnerable demographic and
mostly in low-income countries. Like influenza viruses, many noroviruses are evolving via
a process known as antigenic drift. Antigens are components of infectious agents (includ-
ing viruses) that are recognized by antibodies, proteins that bind to and neutralize foreign
invaders. Over time, noroviruses develop small changes in their antigens that allow them
to escape from antibodies produced in response to earlier infections. Every two to four
years, because of accumulated antigenic drift, a new strain of norovirus emerges to which
the human population has no direct antibody immunity, and an outbreak occurs. Because
vaccines usually contain a component of the infectious agent that stimulates immunity,
antigenic drift complicates the process of vaccine development. To be worth the cost and
effort, a norovirus vaccine must confer immunity against a diverse range of norovirus
strains, ideally including strains beyond those represented within the vaccine itself.
Partly because there is not a reliable method for growing noroviruses in the laboratory, re-
cent efforts have focused on developing candidate vaccines using virus-like particles
(VLPs). VLPs are constructed from laboratory-generated molecules of the virus’s capsid
(outer shell). These capsid proteins self-assemble into icosahedral VLPs, which resemble
the viral shell. VLPs cannot infect people or cause illness, but because they contain viral
antigens, they can induce the immune system to produce antibodies that may neutralize
actual viruses. VLPs can also be used to study the antibodies that people produce in re-
sponse to vaccination or infection.
WhyWas This Study Done?
VLP-based vaccines are relatively new, and their capacity to elicit a broad immune re-
sponse conferring protection to an evolving range of norovirus strains is not established.
One VLP vaccine based on a single strain that circulates primarily in children conferred
immunity to that strain. Another, multivalent (containing a mix of VLPs from more than
one strain) VLP vaccine elicited antibody generation, but in a phase I clinical trial did not
confer immunity to infection by a strain that had previously circulated globally. In the cur-
rent study, the researchers explored two key questions using laboratory analysis of blood
samples drawn from participants in that trial. First, they tested whether the vaccine elicits
antibody responses to a broad range of norovirus strains, as antibody responses can pro-
vide clues to the potential for this type of vaccine to confer broad immunity in the future.
Second, they investigated how preexisting exposure to noroviruses affects the immune sys-
tem’s response to a vaccine—strategic information that could aid in future
vaccine development.
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What Did the Researchers Do and Find?
The researchers tested serum (blood without cells or clotting proteins; serum contains the
antibodies generated by the immune system) collected from ten participants receiving one
injection of the VLP vaccine followed by a second injection 28 days later. They analyzed
the serum specimens for antibodies to vaccine VLPs and also to VLPs representing viruses
that were not contained in the vaccine. They used two methods, both utilizing VLPs gener-
ated from 11 norovirus strains: a traditional method that assesses binding of serum anti-
bodies to each of these VLPs, and a more recent method that assays the ability of
antibodies to block the interaction of each VLP with a molecule on intestinal cells that
binds to the virus (the gut epithelial ligand), enabling norovirus to enter and infect cells.
Prior studies suggest that this latter assay may be a better proxy for actual immunity.
The researchers’major finding is that a multivalent VLP vaccine (two VLPs representing
four strains of norovirus: one from a subgroup called genotype GI.1 and another consen-
sus VLP of three strains from the subgroup GII.4) can rapidly elicit serum antibodies that
bind a range of vaccine and non-vaccine VLPs, and that block binding of these VLPs to
the gut epithelial ligand. Notably, vaccine recipients also generated antibodies reactive to
two novel VLPs representing human noroviruses that they could not have previously en-
countered, indicating that prior exposure to each norovirus strain was not required for the
full antibody response following vaccination. However, based on an analysis of which spe-
cific epitopes (small regions on an antigen) the population of antibodies binds, the authors
report that antibody responses to the vaccine prominently target epitopes of a 1997 strain
of human GII.4 norovirus, and propose that exposure history does influence the
antibody response.
What Do these Findings Mean?
These findings raise the possibility that the VLP vaccine may induce immunity not only to
norovirus strains that have caused past outbreaks, but also to variants that have yet to
enter the population—a necessary attribute given the antigenic drift observed among nor-
oviruses. The study also indicates that VLP-induced antibody responses to norovirus are
consistent with the “antigenic seniority”model, in which strains to which an individual
was previously exposed influence the binding properties of a vaccine-induced antibody
population. This latter finding may influence the design of future norovirus vaccines.
These results must be interpreted cautiously, particularly as they pertain to the potential
for a norovirus vaccine to protect against natural infection. The study is small, and anti-
body binding and blocking assays may not replicate how the immune system of a vaccine
recipient will respond to true norovirus infection. Additionally, the study participants
were all adults aged 18 to 49 years, while a vaccine is most needed for young children (who
account for the majority of severe infections) and the elderly (who are most likely to die
from infection). Unlike the study participants, young children lack preexisting antibodies
to norovirus. Older people are more likely to have been previously exposed to norovirus,
but may show attenuated immune responses to vaccination. Adapting to the different im-
mune responses of these two groups remains a central challenge to norovirus
vaccine development.
Additional Information
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001807.
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• TheWorld Health Organization provides a comprehensive description of the disease
burden from diarrheal disease
• The MedlinePlus encyclopedia has a page on viral gastroenteritis (in English and
Spanish)
• The US Centers for Disease Control and Prevention provides information on disease
trends and outbreaks
• The US Department of Health and Human Services offers guidance for prevention
based on food safety
• A 2014 interview with Academic Editor Benjamin Lopman explores the difficulty of
developing a norovirus vaccine
• The authors have previously published findings on the evolution of norovirus strains in
PLOS Medicine and have discussed the challenges of norovirus therapeutic design in
PLOS Pathogens
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